Purple Net Receivables vs Total Liab Analysis

PPBT Stock

USD 2.19 0.35 13.78%

Purple Biotech financial indicator trend analysis is much more than just breaking down Purple Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Purple Biotech is a good investment. Please check the relationship between Purple Biotech Net Receivables and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Purple Biotech Net Receivables account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Purple Biotech's Net Receivables and Total Liab is 0.45. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Liab in the same time period over historical financial statements of Purple Biotech, assuming nothing else is changed. The correlation between historical values of Purple Biotech's Net Receivables and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Purple Biotech are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Receivables i.e., Purple Biotech's Net Receivables and Total Liab go up and down completely randomly.

Correlation Coefficient

0.45

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Receivables

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Purple Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Purple Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.Enterprise Value is likely to gain to about 11 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.6 M in 2024.

Purple Biotech fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant And Equipment Net	Non Current Assets Total	Property Plant And Equipment Gross	Other Liab	Net Tangible Assets	Short Term Investments	Inventory	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital
Total Assets		0.6	0.65	1.0	-0.76	-0.77	0.57	0.81	0.97	0.28	0.28	0.42	0.08	0.92	0.58	0.97	0.98	0.84	0.98	-0.15	0.89	0.77	0.59	0.96	0.76	0.97
Other Current Liab	0.6		0.92	0.54	-0.67	-0.79	0.63	0.7	0.44	0.27	0.39	0.43	-0.16	0.78	0.76	0.45	0.59	0.71	0.59	-0.04	0.33	0.13	0.66	0.63	0.7	0.53
Total Current Liabilities	0.65	0.92		0.58	-0.74	-0.88	0.76	0.76	0.46	0.51	0.52	0.61	-0.08	0.87	0.87	0.48	0.63	0.79	0.63	0.04	0.34	0.08	0.76	0.71	0.79	0.55
Total Stockholder Equity	1.0	0.54	0.58		-0.73	-0.73	0.53	0.78	0.99	0.24	0.23	0.37	0.1	0.89	0.52	0.99	0.98	0.81	0.98	-0.18	0.91	0.81	0.54	0.95	0.72	0.98
Net Debt	-0.76	-0.67	-0.74	-0.73		0.88	-0.82	-0.97	-0.69	-0.26	-0.63	-0.63	-0.13	-0.85	-0.78	-0.69	-0.7	-0.84	-0.7	0.23	-0.56	-0.27	-0.52	-0.75	-0.66	-0.68
Retained Earnings	-0.77	-0.79	-0.88	-0.73	0.88		-0.94	-0.83	-0.64	-0.43	-0.74	-0.78	0.0	-0.91	-0.95	-0.64	-0.77	-0.97	-0.77	0.19	-0.56	-0.21	-0.69	-0.83	-0.79	-0.73
Accounts Payable	0.57	0.63	0.76	0.53	-0.82	-0.94		0.71	0.43	0.38	0.88	0.85	-0.02	0.75	0.93	0.43	0.59	0.9	0.59	-0.33	0.43	-0.01	0.52	0.69	0.68	0.56
Cash	0.81	0.7	0.76	0.78	-0.97	-0.83	0.71		0.73	0.27	0.47	0.5	0.16	0.89	0.69	0.73	0.74	0.78	0.74	-0.21	0.61	0.37	0.52	0.79	0.7	0.7
Cash And Short Term Investments	0.97	0.44	0.46	0.99	-0.69	-0.64	0.43	0.73		0.17	0.14	0.26	0.17	0.82	0.41	1.0	0.95	0.73	0.95	-0.19	0.91	0.86	0.46	0.89	0.64	0.96
Net Receivables	0.28	0.27	0.51	0.24	-0.26	-0.43	0.38	0.27	0.17		0.16	0.31	0.01	0.45	0.45	0.21	0.29	0.35	0.29	0.24	-0.07	-0.09	0.75	0.29	0.65	0.18
Common Stock Shares Outstanding	0.28	0.39	0.52	0.23	-0.63	-0.74	0.88	0.47	0.14	0.16		0.93	-0.08	0.46	0.83	0.14	0.26	0.71	0.26	-0.21	0.23	-0.27	0.33	0.41	0.36	0.28
Non Current Liabilities Total	0.42	0.43	0.61	0.37	-0.63	-0.78	0.85	0.5	0.26	0.31	0.93		-0.13	0.56	0.89	0.28	0.38	0.79	0.38	0.09	0.3	-0.13	0.54	0.5	0.41	0.4
Other Current Assets	0.08	-0.16	-0.08	0.1	-0.13	0.0	-0.02	0.16	0.17	0.01	-0.08	-0.13		0.09	-0.11	0.16	0.01	-0.09	0.01	-0.1	0.01	0.06	-0.13	-0.02	-0.04	-0.02
Other Stockholder Equity	0.92	0.78	0.87	0.89	-0.85	-0.91	0.75	0.89	0.82	0.45	0.46	0.56	0.09		0.77	0.83	0.9	0.9	0.9	-0.13	0.71	0.49	0.71	0.94	0.87	0.85
Total Liab	0.58	0.76	0.87	0.52	-0.78	-0.95	0.93	0.69	0.41	0.45	0.83	0.89	-0.11	0.77		0.43	0.57	0.9	0.57	0.0	0.34	-0.05	0.72	0.66	0.66	0.54
Total Current Assets	0.97	0.45	0.48	0.99	-0.69	-0.64	0.43	0.73	1.0	0.21	0.14	0.28	0.16	0.83	0.43		0.95	0.74	0.95	-0.14	0.89	0.85	0.5	0.89	0.65	0.96
Property Plant And Equipment Net	0.98	0.59	0.63	0.98	-0.7	-0.77	0.59	0.74	0.95	0.29	0.26	0.38	0.01	0.9	0.57	0.95		0.85	1.0	-0.23	0.9	0.77	0.54	0.98	0.76	0.98
Non Current Assets Total	0.84	0.71	0.79	0.81	-0.84	-0.97	0.9	0.78	0.73	0.35	0.71	0.79	-0.09	0.9	0.9	0.74	0.85		0.85	-0.19	0.71	0.37	0.66	0.9	0.77	0.84
Property Plant And Equipment Gross	0.98	0.59	0.63	0.98	-0.7	-0.77	0.59	0.74	0.95	0.29	0.26	0.38	0.01	0.9	0.57	0.95	1.0	0.85		-0.23	0.9	0.77	0.54	0.98	0.76	0.98
Other Liab	-0.15	-0.04	0.04	-0.18	0.23	0.19	-0.33	-0.21	-0.19	0.24	-0.21	0.09	-0.1	-0.13	0.0	-0.14	-0.23	-0.19	-0.23		-0.37	-0.16	0.38	-0.26	-0.25	-0.23
Net Tangible Assets	0.89	0.33	0.34	0.91	-0.56	-0.56	0.43	0.61	0.91	-0.07	0.23	0.3	0.01	0.71	0.34	0.89	0.9	0.71	0.9	-0.37		0.86	0.21	0.89	0.52	0.94
Short Term Investments	0.77	0.13	0.08	0.81	-0.27	-0.21	-0.01	0.37	0.86	-0.09	-0.27	-0.13	0.06	0.49	-0.05	0.85	0.77	0.37	0.77	-0.16	0.86		0.13	0.68	0.34	0.81
Inventory	0.59	0.66	0.76	0.54	-0.52	-0.69	0.52	0.52	0.46	0.75	0.33	0.54	-0.13	0.71	0.72	0.5	0.54	0.66	0.54	0.38	0.21	0.13		0.54	0.76	0.5
Property Plant Equipment	0.96	0.63	0.71	0.95	-0.75	-0.83	0.69	0.79	0.89	0.29	0.41	0.5	-0.02	0.94	0.66	0.89	0.98	0.9	0.98	-0.26	0.89	0.68	0.54		0.8	0.95
Current Deferred Revenue	0.76	0.7	0.79	0.72	-0.66	-0.79	0.68	0.7	0.64	0.65	0.36	0.41	-0.04	0.87	0.66	0.65	0.76	0.77	0.76	-0.25	0.52	0.34	0.76	0.8		0.69
Net Invested Capital	0.97	0.53	0.55	0.98	-0.68	-0.73	0.56	0.7	0.96	0.18	0.28	0.4	-0.02	0.85	0.54	0.96	0.98	0.84	0.98	-0.23	0.94	0.81	0.5	0.95	0.69

Click cells to compare fundamentals

Purple Biotech Account Relationship Matchups

Purple Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.7M	83.8M	70.2M	54.6M	44.3M	32.4M
Other Current Liab	1.1M	1.7M	2.6M	4.7M	3.5M	2.2M
Total Current Liabilities	3.5M	3.1M	4.3M	7.1M	7.2M	3.7M
Total Stockholder Equity	10.4M	79.4M	64.8M	46.9M	34.2M	27.6M
Net Debt	(4.2M)	(10.4M)	(10.1M)	(14.5M)	(14.1M)	(13.4M)
Retained Earnings	(49.5M)	(77.5M)	(95.9M)	(117.6M)	(137.5M)	(130.6M)
Accounts Payable	1.2M	1.2M	1.5M	2.1M	3.5M	3.7M
Cash	4.4M	11.2M	10.9M	15.0M	14.5M	8.4M
Cash And Short Term Investments	6.4M	57.8M	47.2M	32.1M	15.4M	19.6M
Common Stock Shares Outstanding	1.9M	17.2M	17.8M	18.5M	221.3M	232.4M
Liabilities And Stockholders Equity	14.7M	83.8M	70.2M	54.6M	44.3M	32.4M
Non Current Liabilities Total	313K	953K	842K	466K	2.8M	3.0M
Other Current Assets	1.9M	977K	1.3M	1.1M	376K	357.2K
Other Stockholder Equity	56.9M	118.9M	124.0M	126.4M	133.2M	72.8M
Total Liab	3.9M	4.1M	5.1M	7.5M	10.0M	10.5M
Total Current Assets	8.3M	59.3M	48.5M	33.3M	15.8M	20.9M
Accumulated Other Comprehensive Income	3.1M	8.0M	8.8M	10.1M	38.5M	40.4M
Property Plant And Equipment Net	244K	968K	896K	682K	470K	409.3K
Non Current Assets Total	6.4M	24.5M	21.7M	21.4M	28.5M	29.9M
Property Plant And Equipment Gross	244K	968K	896K	682K	470K	409.3K
Other Liab	285K	265K	292K	145K	130.5K	124.0K
Net Tangible Assets	4.2M	58.9M	44.3M	26.2M	30.2M	24.0M
Short Term Investments	2.0M	46.6M	36.3M	17.1M	923K	876.9K
Property Plant Equipment	244K	968K	896K	682K	784.3K	451.2K
Net Invested Capital	10.4M	79.4M	64.8M	46.9M	34.2M	39.9M
Net Working Capital	4.8M	56.2M	44.2M	26.2M	8.6M	8.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC